Cited by 1,134Melanoma and MAPK PathwaysLung Cancer Treatments and MutationsCancer Mechanisms and Therapy

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Open access

Wilson, Timothy R., Fridlyand, Jane, Yan, Yibing, Penuel, Elicia, Burton, Luciana, Chan, Emily, Peng, Jing, Lin, Eva, Wang, Yulei, Sosman, Jeff, Ribas, Antoni, Li, Jiang, Moffat, John, Sutherlin, Daniel P., Koeppen, Hartmut, Merchant, Mark, Neve, Richard, Settleman, Jeff·2012·Nature

DOI 10.1038/nature11249PMC PMC3724525

Open this paper in CoChat — free account

Abstract

Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy. However, the efficacy of kinase inhibitors in patients whose tumours harbour such alleles is invariably limited by innate or acquired drug resistance. The identification of resistance mechanisms has revealed a recurrent theme—the engagement of survival signals redundant to those transduced by the targeted kinase. Cancer cells typically express multiple receptor tyrosine kinases (RTKs) that mediate signals that converge on common critical downstream cell-survival effectors—most notably, phosphatidylinositol-3-OH kinase (PI(3)K) and mitogen-activated protein kinase (MAPK). Consequently, an increase in RTK-ligand levels, through autocrine tumour-cell production, paracrine contribution from tumour stroma or systemic production, could confer resistance to inhibitors of an oncogenic kinase with a similar signalling output. Here, using a panel of kinase-'addicted' human cancer cell lines, we found that most cells can be rescued from drug sensitivity by simply exposing them to one or more RTK ligands. Among the findings with clinical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the BRAF inhibitor PLX4032 (vemurafenib) in BRAF-mutant melanoma cells. These observations highlight the extensive redundancy of RTK-transduced signalling in cancer cells and the potentially broad role of widely expressed RTK ligands in innate and acquired resistance to drugs targeting oncogenic kinases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature11249

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,244
Friends or foes — bipolar effects of the tumour stroma in cancer
Mueller, M. M., & Fusenig, N. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1477 · Cited by 1,817
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Self-citation
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
Turke, A. B., Zejnullahu, K., Wu, Y.-L., Song, Y., Dias-Santagata, D., Lifshits, E., Toschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.022 · Cited by 1,059

Show all 29 references

Sorted by citations

Items 101–200 of 1,000

Phenotype Switching: Tumor Cell Plasticity as a Resistance Mechanism and Target for Therapy
Kemper, K., de Goeje, P. L., Peeper, D. S., & van Amerongen, R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1174 · Cited by 216
Carcinoma‐associated fibroblasts: Non‐neoplastic tumour‐promoting mesenchymal cells
Polanska, U. M., & Orimo, A. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24347 · Cited by 208
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
Cui, J. J. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401427c · Cited by 216
Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF V600 -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
Johnson, D. B., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Kefford, R. F., Hamid, O., Schuchter, L. M., Cebon, J. S., Sharfman, W. H., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.3535 · Cited by 219
Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
Girotti, M. R., Lopes, F., Preece, N., Niculescu-Duvaz, D., Zambon, A., Davies, L., Whittaker, S., Saturno, G., Viros, A., Pedersen, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.006 · Cited by 212
Futibatinib Is a Novel Irreversible FGFR 1–4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors
Sootome, H., Fujita, H., Ito, K., Ochiiwa, H., Fujioka, Y., Ito, K., Miura, A., Sagara, T., Ito, S., Ohsawa, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2568 · Cited by 165
Tumor Microenvironment and Metabolic Synergy in Breast Cancers: Critical Importance of Mitochondrial Fuels and Function
Martinez‐Outschoorn, U., Sotgia, F., & Lisanti, M. P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.03.002 · Cited by 211
The Met receptor tyrosine kinase: A key player in oncogenesis and drug resistance
Maroun, C. R., & Rowlands, T. M. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.014 · Cited by 206
Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Phillips, G. D. L., Fields, C. T., Li, G., Dowbenko, D. J., Schaefer, G., Miller, K. D., André, F., Burris, H. A., Albain, K. S., Harbeck, N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0358 · Cited by 198
Targeting oncogenic Raf protein-serine/threonine kinases in human cancers
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.08.013 · Cited by 199
Targeting CAFs to overcome anticancer therapeutic resistance
Saw, P. E., Chen, J., & Song, E. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.03.001 · Cited by 206
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Nathanson, K. L., Martin, A., Wubbenhorst, B. S., Greshock, J. D., Letrero, R., D'Andrea, K. P., O'Day, S. J., Infante, J. R., Falchook, G. S., Arkenau, H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0827 · Cited by 200
Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells
Li, G., Guo, J., Shen, B., Yadav, D. B., Sliwkowski, M. X., Crocker, L., Lacap, J. A., & Phillips, G. D. L. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0296 · Cited by 200
Primary Patient-Derived Cancer Cells and Their Potential for Personalized Cancer Patient Care
Kodack, D. P., Farago, A. F., Dastur, A., Held, M. A., Dardaei, L., Friboulet, L., von Flotow, F., Damon, L. J., Lee, D., Parks, M. K., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.051 · Cited by 196
MMP-9 expression varies according to molecular subtypes of breast cancer
Yousef, E. M., Tahir, M. R., St‐Pierre, Y., & Gaboury, L. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-609 · Cited by 196
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
Martz, C. A., Ottina, K. A., Singleton, K. R., Jasper, J. S., Wardell, S. E., Peraza-Penton, A., Anderson, G. R., Winter, P. S., Wang, T., Alley, H. M., et al. (2014) · Science Signaling · doi:10.1126/scisignal.aaa1877 · Cited by 189
An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors
Jonas, O., Landry, H. M., Fuller, J. E., Santini, J. T., Baselga, J., Tepper, R. I., Cima, M. J., & Langer, R. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010564 · Cited by 189
Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer
Cabanos, H. F., & Hata, A. N. (2021) · Cancers · doi:10.3390/cancers13112666 · Cited by 189
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene
Hall, A., Meyle, K. D., Lange, M. K., Klima, M., Sanderhoff, M., Dahl, C., Abildgaard, C., Thorup, K., Moghimi, S. M., Jensen, P. B., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.965 · Cited by 191
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
Simpson, A. D., Kamdoum, W. V. P., Macaulay, V. M., Weyer-Czernilofsky, U., & Bogenrieder, T. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0514-5 · Cited by 190
Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
Baenke, F., Chaneton, B., Smith, M., van den Broek, N. J. F., Hogan, K., Tang, H., Virós, A., Martin, M. J., Galbraith, L. C. A., Girotti, M. R., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.08.003 · Cited by 191
B-cell precursor acute lymphoblastic leukemia cells use tunneling nanotubes to orchestrate their microenvironment
Polak, R., de Rooij, B., Pieters, R., & den Boer, M. L. (2015) · Blood · doi:10.1182/blood-2015-03-634238 · Cited by 188
A framework for understanding and targeting residual disease in oncogene-driven solid cancers
Bivona, T. G., & Doebele, R. C. (2016) · Nature Medicine · doi:10.1038/nm.4091 · Cited by 184
Mitochondrial oxidative stress is the achille's heel of melanoma cells resistant to Braf-mutant inhibitor
Corazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet‐Martino, M., Balayssac, S., Rocchi, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1420 · Cited by 188
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors
Anastas, J. N., Kulikauskas, R. M., Tamir, T. Y., Rizos, H., Long, G. V., von Euw, E. M., Yang, P., Chen, H., Haydu, L. E., Toroni, R. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70156 · Cited by 184
A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer
Wilson, F. H., Johannessen, C. M., Piccioni, F., Tamayo, P., Kim, J. W., Allen, E. M. V., Corsello, S. M., Capelletti, M., Calles, A., Butaney, M., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.005 · Cited by 178
Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing
Vörsmann, H., Groeber, F., Walles, H., Busch, S., Beissert, S., Walczak, H., & Kulms, D. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.249 · Cited by 168
PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugs
Prahallad, A., Heynen, G. J. J. E., Germano, G., Willems, S. M., Evers, B., Vecchione, L., Gambino, V., Lieftink, C., Beijersbergen, R. L., Di Nicolantonio, F., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.037 · Cited by 168
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., Meyer, A. S., Im, H., Frederick, D. T., Tadros, J., Griffith, L. G., Lee, H., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0933 · Cited by 168
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Traer, E. A., Martinez, J., Javidi‐Sharifi, N., Agarwal, A., Dunlap, J. B., English, I. A., Kovacsovics, T. J., Tyner, J. W., Wong, M. H., & Druker, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3569 · Cited by 168
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity
Ilkow, C. S., Marguerie, M., Batenchuk, C., Mayer, J., Ben Neriah, D., Cousineau, S., Falls, T., Jennings, V. A., Boileau, M., Bellamy, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3848 · Cited by 165
Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation
Baltschukat, S., Engstler, B. S., Huang, A., Hao, H.-X., Tam, A., Wang, H. Q., Liang, J., DiMare, M. T., Bhang, H.-E. C., Wang, Y., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2814 · Cited by 167
Mechanisms of lapatinib resistance in HER2-driven breast cancer
D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., Placido, S. D., Rosa, R., & Bianco, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.001 · Cited by 169
Recent advances in understanding tumor stroma-mediated chemoresistance in breast cancer
Plavá, J., Cihova, M., Buríková, M., Matúšková, M., Kučerová, L., & Miklikova, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0960-z · Cited by 165
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy
Tavora, B., Reynolds, L. E., Batista, S., Demircioglu, F., Fernandez, I., Lechertier, T., Lees, D. M., Wong, P.-P., Alexopoulou, A., Elia, G., et al. (2014) · Nature · doi:10.1038/nature13541 · Cited by 163
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
Salgia, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0472 · Cited by 162
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., Ottaviano, V., & Queirolo, P. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s39096 · Cited by 163
Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies
Sun, C., & Bernards, R. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.08.010 · Cited by 155
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158
Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target
Togo, S., Polanska, U. M., Horimoto, Y., & Orimo, A. (2013) · Cancers · doi:10.3390/cancers5010149 · Cited by 162
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
Qu, Z., Wu, J., Wu, J., Luo, D., Jiang, C., & Ding, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0430-z · Cited by 156
The Gastrointestinal Tumor Microenvironment
Quante, M., Varga, J., Wang, T. C., & Greten, F. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.052 · Cited by 154
Network quantification of EGFR signaling unveils potential for targeted combination therapy
Klinger, B., Sieber, A., Fritsche‐Guenther, R., Witzel, F., Berry, L., Schumacher, D., Yan, Y., Durek, P., Merchant, M. A., Schäfer, R., et al. (2013) · Molecular Systems Biology · doi:10.1038/msb.2013.29 · Cited by 155
Intratumoral Heterogeneity: From Diversity Comes Resistance
Pribluda, A., de la Cruz, C. C., & Jackson, E. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1213 · Cited by 160
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance
Joshi, S. K., Nechiporuk, T., Bottomly, D., Piehowski, P., Reisz, J. A., Pittsenbarger, J., Kaempf, A. J., Gosline, S. J. C., Wang, Y.-T., Hansen, J., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.003 · Cited by 152
Surviving apoptosis: life–death signaling in single cells
Flusberg, D. A., & Sorger, P. K. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.03.003 · Cited by 149
The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma.
McCain, J. (2013) · Europe PMC (PubMed Central) · Cited by 146
Redox control of glutamine utilization in cancer
Alberghina, L., & Gaglio, D. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.513 · Cited by 150
MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
Luraghi, P., Reato, G., Cipriano, E., Sassi, F., Orzan, F., Bigatto, V., De Bacco, F., Menietti, E., Han, M., Rideout, W. M., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2340-t · Cited by 146
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
WILSON, C. A., Nicholes, K., Bustos, D. J., Lin, E., Song, Q., Stéphan, J.-P., Kirkpatrick, D. S., & Settleman, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2397 · Cited by 149
Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review
Proietti, I., Skroza, N., Bernardini, N., Tolino, E., Balduzzi, V., Marchesiello, A., Michelini, S., Volpe, S., Mambrin, A., Mangino, G., et al. (2020) · Cancers · doi:10.3390/cancers12102801 · Cited by 153
Next‐generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity
Catenacci, D. V. T. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 143
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models
Xia, W., Petricoin, E., Zhao, S., Liu, L.-H., Osada, T., Cheng, Q., Wulfkuhle, J. D., Gwin, W. R., Yang, X., Gallagher, R. I., et al. (2013) · Breast Cancer Research · doi:10.1186/bcr3480 · Cited by 143
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines
Niepel, M., Hafner, M., Mills, C. E., Subramanian, K., Williams, E. H., Chung, M., Gaudio, B., Barrette, A. M., Stern, A. D., Hu, B., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.06.005 · Cited by 133
TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma
Corcoran, R. B., Rothenberg, S. M., Hata, A. N., Faber, A. C., Piris, A., Nazarian, R. M., Brown, R. D., Godfrey, J. T., Winokur, D., Walsh, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005753 · Cited by 140
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
Nguyen, T. V., Sleiman, M., Moriarty, T., Herrick, W. G., & Peyton, S. R. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.058 · Cited by 142
Fibroblast-mediated drug resistance in cancer
Paraiso, K. H. T., & Smalley, K. S. M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.01.018 · Cited by 147
Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Krepler, C., Xiao, M., Sproesser, K., Brafford, P. A., Shannan, B., Beqiri, M., Liu, Q., Xu, W., Garman, B., Nathanson, K. L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1762 · Cited by 141
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 139
Bone marrow stroma‐mediated resistance to FLT 3 inhibitors in FLT 3‐ ITD AML is mediated by persistent activation of extracellular regulated kinase
Yang, X., Sexauer, A. N., & Levis, M. J. (2013) · British Journal of Haematology · doi:10.1111/bjh.12599 · Cited by 139
The mitogen-activated protein kinase pathway in melanoma part I – Activation and primary resistance mechanisms to BRAF inhibition
Amaral, T. M. S., Sinnberg, T. W., Meier, F. E., Krepler, C., Levesque, M. P., Niessner, H., & Garbe, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.010 · Cited by 138
The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation
Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0257 · Cited by 132
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, D., Karreth, F. A., Rust, A. G., Pérez-Mancera, P. A., Rashid, M., Iorio, F., Alifrangis, C., Arends, M. J., Bosenberg, M., Bollag, G. E., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418163112 · Cited by 139
Systemic Therapy for Hepatocellular Carcinoma: The Issue of Treatment Stage Migration and Registration of Progression Using the BCLC-Refined RECIST
Reig, M., Darnell, A., Forner, A., Rimola, J., Ayuso, C., & Bruix, J. (2014) · Seminars in Liver Disease · doi:10.1055/s-0034-1394143 · Cited by 135
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
Niezgoda, A., Niezgoda, P., & Czajkowski, R. (2015) · BioMed Research International · doi:10.1155/2015/851387 · Cited by 138
BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth
Wang, T., Xiao, M., Ge, Y., Krepler, C., Belser, E., López-Coral, A., Xu, X., Zhang, G., Azuma, R., Liu, Q., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1554 · Cited by 134
Can we unlock the potential of IGF-1R inhibition in cancer therapy?
King, H., Aleksic, T., Haluska, P., & Macaulay, V. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.07.004 · Cited by 135
Targeting RAS -mutant Cancers: Is ERK the Key?
Ryan, M. B., Der, C. J., Wang‐Gillam, A., & Cox, A. D. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 133
Elevated hepatocyte growth factor expression as an autocrine c‐Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells
Karagonlar, Z. F., Koç, D., İşcan, E., Erdal, E., & Atabey, N. (2016) · Cancer Science · doi:10.1111/cas.12891 · Cited by 132
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
Owusu, B. Y., Galemmo, R. A., Janetka, J. W., & Klampfer, L. (2017) · Cancers · doi:10.3390/cancers9040035 · Cited by 140
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Rusan, M., Li, K., Li, Y. Y., Christensen, C. L., Abraham, B. J., Kwiatkowski, N. P., Buczkowski, K. A., Bockorny, B., Chen, T., Li, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0461 · Cited by 128
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128
Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
Romano, E., Pradervand, S., Paillusson, A., Weber, J., Harshman, K., Muehlethaler, K., Speiser, D. E., Peters, S., Rimoldi, D., & Michielin, O. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0661 · Cited by 130
The tumor microenvironment controls drug sensitivity
Östman, A. (2012) · Nature Medicine · doi:10.1038/nm.2938 · Cited by 135
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma
Kwong, L. N., Boland, G. M., Frederick, D. T., Helms, T. L., Akid, A. T., Miller, J. P., Jiang, S., Cooper, Z. A., Song, X., Seth, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78954 · Cited by 120
Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3 -Mutant Cancer
Herrera-Abreu, M. T., Pearson, A., Campbell, J., Shnyder, S. D., Knowles, M. A., Ashworth, A., & Turner, N. C. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0569 · Cited by 131
Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases
Isozaki, H., Ichihara, E., Takigawa, N., Ohashi, K., Ochi, N., Yasugi, M., Ninomiya, T., Yamane, H., Hotta, K., Sakai, K., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1010 · Cited by 128
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions
Bergamo, A., Dyson, P. J., & Sava, G. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.009 · Cited by 131
Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies
Yoshida, G. J., Azuma, A., Miura, Y., & Orimo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092256 · Cited by 131
Tumour Cell Heterogeneity
Gay, L. J., Baker, A., & Graham, T. A. (2016) · F1000Research · doi:10.12688/f1000research.7210.1 · Cited by 129
The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas
Mezawa, Y., & Orimo, A. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2471-1 · Cited by 127
A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
Hensing, T. A., Chawla, A., Batra, R., & Salgia, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8778-4_5 · Cited by 127
Nanoparticle drug delivery systems for synergistic delivery of tumor therapy
Chen, D., Liu, X., Lu, X., & Tian, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1111991 · Cited by 142
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
Spagnolo, F., Ghiorzo, P., & Queirolo, P. (2014) · Oncotarget · doi:10.18632/oncotarget.2602 · Cited by 128
Overcoming resistance to BRAF inhibitors
Arozarena, I., & Wellbrock, C. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.09 · Cited by 131
ALK inhibitor resistance in ALKF1174L-driven neuroblastoma is associated with AXL activation and induction of EMT
Debruyne, D. N., Bhatnagar, N., Sharma, B., Luther, W., Moore, N. F., Cheung, N., Gray, N. S., & George, R. E. (2015) · Oncogene · doi:10.1038/onc.2015.434 · Cited by 121
Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance
Chen, F., Long, Q., Fu, D., Zhu, D., Ji, Y., Han, L., Zhang, B., Xu, Q., Liu, B., Li, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06860-4 · Cited by 124
Spatial competition constrains resistance to targeted cancer therapy
Bačević, K., Noble, R., Soffar, A. A., Ammar, O., Boszonyik, B., Prieto, S., Vincent, C., Hochberg, M., Krasińska, L., & Fisher, D. (2017) · Nature Communications · doi:10.1038/s41467-017-01516-1 · Cited by 115
Trial Watch
Vacchelli, E., Galluzzi, L., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.20459 · Cited by 122
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
Deblois, G., Smith, H. W., Tam, I. S., Gravel, S., Caron, M., Savage, P., Labbé, D. P., Bégin, L. R., Tremblay, M. L., Park, M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12156 · Cited by 124
Immune checkpoint blockade immunotherapy to activate anti‐tumour T ‐cell immunity
Ramsay, A. G. (2013) · British Journal of Haematology · doi:10.1111/bjh.12380 · Cited by 123
Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma
Roesch, A. (2014) · Oncogene · doi:10.1038/onc.2014.249 · Cited by 123
RETRACTED ARTICLE: SFRP2 augments WNT16B signaling to promote therapeutic resistance in the damaged tumor microenvironment
Sun, Y., Zhu, D., Chen, F., Qian, M., Wei, H., Chen, W., & Xu, J. (2016) · Oncogene · doi:10.1038/onc.2015.494 · Cited by 112
Retracted
Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy
Asgharzadeh, M. R., Barar, J., Pourseif, M. M., Eskandani, M., Niya, M. J., Mashayekhi, M. R., & Omidi, Y. (2017) · Bioimpacts · doi:10.15171/bi.2017.15 · Cited by 118
Signaling cross-talk in the resistance to HER family receptor targeted therapy
Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118
Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights
Meador, C. B., & Hata, A. N. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107522 · Cited by 119
Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
Held, M. A., Langdon, C. G., Platt, J. T., Graham-Steed, T., Liu, Z. Z., Chakraborty, A. K., Bacchiocchi, A., Koo, A., Haskins, J. W., Bosenberg, M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0408 · Cited by 114
HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
Papaccio, F., Della Corte, C. M., Viscardi, G., Di Liello, R., Esposito, G., Sparano, F., Ciardiello, F., & Morgillo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113595 · Cited by 110
Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways
Zhou, B., Sun, C., Li, N., Shan, W., Lü, H., Guo, L., Guo, E., Xia, M., WENG, D., Li, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3442 · Cited by 108

Authors: Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., Ribas, A., Li, J., Moffat, J., Sutherlin, D. P., Koeppen, H., Merchant, M., Neve, R., & Settleman, J.
Affiliations: Genentech (US)
Vanderbilt University Medical Center (US)
University of California, Los Angeles (US)
Corresponding author: Settleman, Jeff
ORCID: Wilson, Timothy R.
Penuel, Elicia
Chan, Emily
Peng, Jing
Lin, Eva
Wang, Yulei
Ribas, Antoni
Koeppen, Hartmut
Merchant, Mark
Neve, Richard
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2012-07
Volume: 487
Issue: 7408
Pages: 505-509
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature11249
PMC: PMC3724525
OpenAlex: W1999025555
Cited by: 1,134
References: 29
Citations by year: 2026: 23 · 2025: 16 · 2024: 31 · 2023: 46 · 2022: 47 · 2021: 51 · 2020: 65 · 2019: 70 · 2018: 85 · 2017: 87 · 2016: 125 · 2015: 137 · 2014: 166 · 2013: 150 · 2012: 34
FWCI: 62.91
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: National Cancer Institute (K24CA097588)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
Keywords: drug resistance, kinase inhibitors, receptor tyrosine kinase, growth factors, hepatocyte growth factor, BRAF inhibitors, vemurafenib, melanoma, tumor microenvironment, phosphatidylinositol 3-kinase, mitogen-activated protein kinase, combination therapy
MeSH terms: Lapatinib, Vemurafenib, Antineoplastic Agents, Breast Neoplasms, Cell Survival, Female, Humans, Indoles, Ligands, Melanoma, Quinazolines, Sulfonamides, Signal Transduction, Hepatocyte Growth Factor, Erb-b2 Receptor Tyrosine Kinases, Receptor, ErbB-2, Drug Resistance, Neoplasm, Phosphatidylinositol 3-Kinases, Receptor Protein-Tyrosine Kinases, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks